Quantcast

Latest Intravenous immunoglobulin Stories

2011-07-28 07:22:03

(Ivanhoe Newswire) -- A new treatment for hard-to-match kidney transplant patients is providing dramatic survival benefits. According to the study, hard-to-match transplant candidates who receive a new treatment designed to make their bodies more accepting of incompatible organs are twice as likely to survive eight years after transplant surgery as those who stay on dialysis for years waiting for compatible organs. It's estimated that there is more than 20,000 hard-to-match transplant...

2011-05-24 15:47:00

WASHINGTON, May 25, 2011 /PRNewswire-USNewswire/ -- The Immune Deficiency Foundation (IDF) applauds Representatives Kevin Brady (R-TX) and Doris Matsui (D-CA) and Senators John Kerry (D-MA) and Lamar Alexander (R-TN) for introducing H.R. 1845 and S. 960, both entitled the Medicare IVIG Access Act. With strong bipartisan support, the bills provide for a study of issues relating to access to intravenous immunoglobulin (IVIG) for Medicare beneficiaries in all care settings and a demonstration...

2011-04-04 07:00:00

CINCINNATI, April 4, 2011 /PRNewswire/ -- CarePoint Partners (CarePoint) today announced at the National Home Infusion Association Annual Conference in Orlando, Florida that it has acquired Infusion Technologies, a provider of home infusion therapies including antibiotics, IVIG, nutrition, the associated nursing services and a variety of specialty injections, with locations in North Miami and Tampa. This new market presence strengthens the CarePoint Partners footprint in Florida by...

2011-03-21 16:00:00

KING OF PRUSSIA, Pa., March 21, 2011 /PRNewswire/ -- Data presented by CSL Behring today suggest that treatment with higher dose Hizentra® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI). These data, presented at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting, derived from two recent trials of Hizentra, one performed in the United States and one in the European...

2011-03-19 11:45:00

KING OF PRUSSIA, Pa., March 19, 2011 /PRNewswire/ -- CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision. The new PK model provides a novel means of simulating the mechanism by which SC IgG is transported after it is injected into the subcutaneous tissue....

2011-02-03 06:00:00

LOS ANGELES, Feb. 3, 2011 /PRNewswire/ -- Grifols, Inc. today announced that it has expanded the company's PatientCare Program to offer immune globulins (IVIG) to the Primary Immune Deficiency community (PID). The program will provide Flebogamma® 5% DIF (Immune Globulin Intravenous (Human)) or Flebogamma® 10% DIF (Immune Globulin Intravenous (Human)) at no cost to patients with PID when insurance coverage is not available. The PatientCare Program...

2010-11-22 07:00:00

LOS ANGELES, Nov. 22, 2010 /PRNewswire/ -- Grifols today announced availability of its recently approved Flebogamma® 10% DIF intravenous immune globulin. Grifols is a global healthcare company specializing in bioscience medicines derived from human plasma. Approval from the US Food and Drug Administration (FDA) for Flebogamma® 10% DIF was obtained in July 2010 and final approval in Europe is expected before the end of the year. Today's announcement...

2010-11-18 15:27:00

ANAHEIM, Calif., Nov. 18, 2010 /PRNewswire/ -- Crescent Healthcare today announced a planned expansion of their east coast operations in 2011. They signed a lease to open an infusion pharmacy in Totowa, New Jersey, central to providing immune globulin therapies and services to current patients in Massachusetts, Maryland, New York, New Jersey, Pennsylvania, Connecticut, Delaware, District of Columbia, and Rhode Island. In addition to supporting current business in the northeast, the new...

2010-10-14 09:22:00

RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI). The newly approved Gamunex-C provides both the intravenous route of administration and a new subcutaneous route of...

2010-10-07 00:00:00

ISTANBUL, Oct. 7 /PRNewswire/ -- Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) is an effective and safe initial therapy for treatment-naive patients with primary immunodeficiency (PI) and may offer an attractive alternative to intravenous IgG (IVIg) therapy in the newly diagnosed, according to data presented today at the XIVth Meeting of the European Society for Immunodeficiencies. The study found that IgG replacement therapy initiated with Vivaglobin in patients...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related